Doctolib vs Infermedica
Two European health AI companies that a practice might see in the same conversation and should not evaluate the same way. Doctolib is infrastructure: the dominant booking and practice platform across France, Germany and Italy, now shipping AI capabilities inside a system practices already run, with the most complete European security posture in this index. Infermedica is a regulated instrument: clinical triage taking a patient from an undifferentiated symptom to a level of care, certified as a Class IIb medical device because that is what telling someone how urgently to seek help requires. The distinction is not a technicality. Scheduling and documentation carry no device obligation; advising on urgency does. If any platform capability drifts toward the second, the regime follows it, and Doctolib publishes no oversight design for its AI capabilities at all.
- It is the dominant digital health infrastructure across three European countries, so the AI reaches practices through a platform they already run rather than through a new integration.
- The security posture is the most complete European one in this index and the portfolio structure behind it is the lesson, since it is built for the regimes that actually govern those markets.
- Provenance of the core speech technology is unusually traceable, which is more than most platform vendors disclose about capability they acquired.
- Triage is the product rather than a capability inside a platform, guiding a patient from an undifferentiated symptom to a level of care over a physician curated knowledge base.
- It is certified as a Class IIb medical device in Europe, which is the correct and much higher bar for software that tells a patient how urgently to seek care.
- Being interface first means it embeds inside other organisations' products rather than requiring them to adopt a platform.
Side by Side
| Axis | D Doctolib |
I Infermedica |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Patient Voice Agents page.
The regulatory asymmetry is the decisive fact and it is easy to miss when both vendors are described as European AI: telling a patient what level of care to seek is regulated as a medical device and Infermedica holds that certification, while scheduling, documentation and practice management capabilities are not. If any Doctolib capability moves toward advising on urgency, that boundary applies to it too.
Doctolib publishes no governance framework or evaluation for its AI capabilities and no oversight design for either of them. Neither publishes pricing for the AI layer, and neither publishes accuracy evidence for triage or documentation output.